🇺🇸 FDA
Patent

US 9982265

Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury

granted A61KA61K31/275A61K31/497

Quick answer

US patent 9982265 (Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury) held by The Board of Regents of the University of Texas System expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/275, A61K31/497, A61K31/506, A61K31/519